Episode
Part Two: 50 Million in Funding, 10,000 New Clinics, and the Mistake That Could Kill the Psychedelic Revolution | Dr. Rick Doblin
- Podcast
- Mayim Bialik's Breakdown
- Published
- Jun 3, 2026
- Duration seconds
- 4687
- Processing state
not_requested
Actions
POST https://stenobird.com/v1/public/podcasts/mayim-bialik-s-breakdown-1365756/episodes/part-two-50-million-in-funding-10-000-new-clinics-and-the-mistake-that-could-kill-the-psychedelic-revolution-dr-rick-doblin/transcription-requests
Idempotently request low-priority transcript generation for this episode.GET https://stenobird.com/podcast/mayim-bialik-s-breakdown-1365756/part-two-50-million-in-funding-10-000-new-clinics-and-the-mistake-that-could-kill-the-psychedelic-revolution-dr-rick-doblin.md
Read the agent-friendly Markdown representation of this episode resource.
Summary
Dr. Rick Doblin (founder and president of the Multidisciplinary Association for Psychedelic Studies, and one of the most influential figures in psychedelic science) returns to Mayim Bialik's Breakdown for one of the most controversial and eye-opening conversations on psychedelics we've had yet. From the shocking experiment where scientists gave MDMA to an octopus, to why ibogaine may be the most powerful AND dangerous psychedelic ever studied, this episode explores the future of psychedelic therapy, trauma healing, addiction recovery, policy reform, and human consciousness itself. We break down Trump’s new executive order accelerating psychedelic research and what it could mean for the future legalization of psychedelic-assisted therapy in America. Dr. Doblin explains why veterans suffering from PTSD and disabilities have become central to bipartisan support for psychedelics, and why this issue is now reshaping politics on both sides of the aisle. We also dive deep into ibogaine: its mysterious origins, its ability to help reset opioid addiction, its connection to ancestral memory and intergenerational trauma, why it carries serious risks, and why Dr. Doblin still believes its benefits may outweigh the dangers. He also shares his own profound ibogaine experience that helped him confront perfectionism and his fear of death. Dr. Doblin discusses: - How psychedelics help people integrate trauma - Why psychedelics are generally considered non-addictive - Difference between recreational vs therapeutic psychedelic use - Why psychedelic treatment should be customized to each patient - Importance of integration, peer support, and paying attention to dreams after treatment - Measures of success in MDMA-assisted couples therapy - Origins of the opioid epidemic - "Psychedelic chu…